Global Preventive Vaccine Market Size By Type (Product Type I, Product Type II), By Application (Pediatric Vaccine, Adult Vaccine), By Region, And Segment Forecasts, 2023 to 2032

The Global Preventive Vaccine Market was valued at USD 48.6 billion in 2023 and is projected to reach USD 97.4 billion by 2031, growing at a CAGR of 9.0% during the forecast period from 2023 to 2031. The market is driven by the increasing prevalence of infectious diseases, government immunization initiatives, advancements in biotechnology, and rising public awareness about disease prevention. Preventive vaccines, designed to prime the immune system against potential infections, continue to be central to global public health strategies, especially in low- and middle-income countries.

Drivers

1. Rising Global Immunization Programs

Governments and global health organizations such as WHO and GAVI are actively supporting vaccination campaigns, particularly in developing regions. This ongoing push toward universal immunization coverage significantly fuels market demand.

2. Advancements in Vaccine Technology

Innovations such as mRNA vaccines, recombinant DNA technology, and nanoparticle-based delivery systems are accelerating the development of safer and more effective vaccines for a range of infectious diseases.

3. Public Awareness and Health Infrastructure

An increase in healthcare spending, enhanced access to healthcare services, and growing awareness of the long-term benefits of immunization are contributing to higher vaccination rates globally.

Restraints

1. Vaccine Hesitancy

Despite educational efforts, vaccine hesitancy due to misinformation, religious beliefs, and safety concerns persists in many regions, potentially hindering vaccination coverage.

2. High Costs and Cold Chain Requirements

The production and distribution of vaccines, especially those requiring ultra-cold storage, pose logistical and financial challenges, particularly in rural and low-income settings.

Opportunity

1. Expansion of Adult and Travel Vaccination

Beyond pediatric immunization, the demand for adult vaccines—such as for influenza, shingles, HPV, and travel-related diseases—is growing, creating substantial market opportunities.

2. Emerging Infectious Diseases

The emergence of new pathogens, as seen with COVID-19 and monkeypox, underscores the need for rapid vaccine development platforms and global preparedness, opening avenues for innovation and investment.

Market by Vaccine Type Insights

In 2023, Live Attenuated Vaccines accounted for the largest market share, owing to their robust and long-lasting immune response. However, mRNA-based Vaccines are expected to register the fastest growth through 2031 due to their success during the COVID-19 pandemic and scalable production capabilities. This segment is gaining traction for diseases beyond COVID-19, such as influenza and RSV.

Market by End-use Insights

Government & Public Health Agencies remained the dominant end-use segment in 2023, driven by mass immunization campaigns and national immunization programs. However, the Private & Corporate Healthcare Sector is anticipated to grow rapidly due to employer-sponsored vaccination drives, especially in urban settings and multinational workplaces.

Market by Regional Insights

North America led the global preventive vaccine market in 2023, benefiting from advanced healthcare infrastructure, substantial R&D investments, and high vaccine uptake. Asia-Pacific is expected to witness the fastest CAGR during the forecast period due to increasing healthcare access, rising government initiatives, and large target populations, particularly in India and China.

Competitive Scenario

Key players in the market include Pfizer Inc., GlaxoSmithKline plc, Sanofi S.A., Moderna Inc., Merck & Co., Inc., Bharat Biotech, Serum Institute of India, Johnson & Johnson, CSL Limited, and Novavax Inc. Companies are focusing on expanding vaccine portfolios, investing in novel platforms like mRNA, and forging global distribution alliances.

Scope of Work – Global Preventive Vaccine Market

Key Market Developments

March 2024: Moderna Inc. expanded its mRNA pipeline to include vaccines for RSV and Zika virus, targeting adult and endemic market segments.

September 2023: Pfizer and BioNTech launched a quadrivalent influenza-mRNA combination vaccine in Phase 3 trials, aiming for a 2025 rollout.

July 2023: Serum Institute of India announced a partnership with African Union to scale up vaccine production capacity for regional self-reliance.

November 2022: GlaxoSmithKline launched a new malaria vaccine, Mosquirix, in selected African markets after WHO prequalification.

FAQs

1. What is the current market size of the Global Preventive Vaccine Market?

The market was valued at USD 48.6 billion in 2023.

2. What is the major growth driver of the Global Preventive Vaccine Market?

The major growth driver is the increasing global immunization coverage supported by public health initiatives and technological innovations.

3. Which is the largest region during the forecast period in the Global Preventive Vaccine Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow at the fastest rate through 2031.

4. Which segment accounted for the largest market share in Global Preventive Vaccine Market?

Live Attenuated Vaccines led in 2023, though mRNA vaccines are poised for rapid growth.

5. Who are the key market players in the Global Preventive Vaccine Market?

Key players include Pfizer, GlaxoSmithKline, Sanofi, Moderna, Merck, Bharat Biotech, and Serum Institute of India.